Advertisement
Canada markets open in 2 hours 34 minutes
  • S&P/TSX

    22,265.05
    -108.35 (-0.48%)
     
  • S&P 500

    5,306.04
    +1.32 (+0.02%)
     
  • DOW

    38,852.86
    -216.74 (-0.55%)
     
  • CAD/USD

    0.7319
    -0.0017 (-0.24%)
     
  • CRUDE OIL

    80.46
    +0.63 (+0.79%)
     
  • Bitcoin CAD

    92,794.98
    -822.53 (-0.88%)
     
  • CMC Crypto 200

    1,462.67
    -22.02 (-1.48%)
     
  • GOLD FUTURES

    2,347.00
    -9.50 (-0.40%)
     
  • RUSSELL 2000

    2,066.85
    -2.82 (-0.14%)
     
  • 10-Yr Bond

    4.5420
    +0.0750 (+1.68%)
     
  • NASDAQ futures

    18,811.50
    -129.00 (-0.68%)
     
  • VOLATILITY

    14.09
    +1.17 (+9.06%)
     
  • FTSE

    8,230.71
    -23.47 (-0.28%)
     
  • NIKKEI 225

    38,556.87
    -298.50 (-0.77%)
     
  • CAD/EUR

    0.6742
    -0.0010 (-0.15%)
     

Canopy Growth Stock Is on a Tear: Is it a Good Buy Now?

Cannabis grows at a commercial farm.
Source: Getty Images

Written by Amy Legate-Wolfe at The Motley Fool Canada

It’s been a great month or two for Canopy Growth (TSX:WEED), with shares of the cannabis stock continuing to climb on the back of some positive news — not just for the company but for the United States.

But is it enough? Let’s look at what’s been going on with Canopy Growth stock and whether now is the time to buy or not.

What happened?

First let’s get into what happened for Canopy Growth stock to rise so far. The company saw a surge in share price by up to 80% on the back of cannabis-related news in the United States. News hit the headlines that the Drug Enforcement Administration (DEA) would be going forward with reclassifying marijuana.

ADVERTISEMENT

This is huge news and something the Biden administration has been working on since coming into office. While many states now legalize marijuana, it is still classified federally as a Schedule I substance by the DEA. This classification puts it in the same category as strong substances like heroin.

Now, the DEA should announce soon that it is looking to reclassify the drug as a Schedule III substance. This would put it in the same category as something like Tylenol with codeine — still a controlled substance, but with far less attached to it, and that includes stigmas.

Yet, there are still hurdles to overcome. As of now, this is just rumour. The DEA will have to confirm this and then go on to public hearings. Furthermore, the reclassification likely wouldn’t come down until late this year or, indeed, next year. And even then, should former president Trump be reelected, he could choose to veto the move.

Is enough already there?

So, the question is whether there is already enough reason to invest in Canopy Growth stock. Even without all this news coming from the United States. It’s unclear. The company has certainly been moving ahead with a focus on U.S. legalization. This includes acquisitions that are coming online and would prepare the stock for growth.

But what about earnings? Over the past few quarters, we can paint a clearer picture of whether Canopy Growth stock looks strong enough as a company to invest in. For that, we’ll go back over the last three quarters, with the fourth-quarter and full-year earnings coming up for Canopy Growth stock.

During the first quarter of 2023, the stock reported revenue of $108.7 million, with a net loss of $41.9 million and free cash flow at a loss of $150.7 million. By the second quarter, net revenue fell to $69.6 million, with a net loss rising to $148.2 million and free cash flow improving to a loss of $67.1 million. So, it wasn’t looking great.

However, there were some improvements by the third quarter. Net revenue rose to $78.5 million, though the net loss widened to $230.3 million. Free cash flow also improved further, however, hitting a loss of $33.9 million.

Bottom line

Despite a lot of improvements and a lot of news from the U.S., Canopy Growth stock continues to trade at a hefty loss. That being said, it’s focusing more on its profitable businesses and could achieve profitability quite soon — especially if the company is able to further expand in the United States. So, while it may not be a stellar buy at the moment, continue to keep your eye on Canopy Growth stock.

The post Canopy Growth Stock Is on a Tear: Is it a Good Buy Now?  appeared first on The Motley Fool Canada.

Should you invest $1,000 in Canopy Growth right now?

Before you buy stock in Canopy Growth, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Canopy Growth wasn’t one of them. The 10 stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $15,578.55!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 32 percentage points since 2013*.

See the 10 stocks * Returns as of 3/20/24

More reading

Fool contributor Amy Legate-Wolfe owns shares of Canopy Growth Corporation. The Motley Fool has a disclosure policy.

2024